These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3350393)

  • 1. Characterization of commercially available plasminogen preparations in vitro: purity and reactivity.
    Miyashita C; Heiden M; Leipnitz G; Pindur G; Wenzel E
    Haemostasis; 1988; 18 Suppl 1():121-6. PubMed ID: 3350393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a fucoidan on the activation of plasminogen by u-PA and t-PA.
    Nishino T; Yamauchi T; Horie M; Nagumo T; Suzuki H
    Thromb Res; 2000 Sep; 99(6):623-34. PubMed ID: 10974349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET; Mack DL; Sobel BE
    Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y; Scully MF; Ellis V; Kakkar VV
    Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport of urokinase across the intestinal tract of normal human subjects with stimulation of synthesis and/or release of urokinase-type proteins.
    Toki N; Sumi H; Sasaki K; Boreisha I; Robbins KC
    J Clin Invest; 1985 Apr; 75(4):1212-22. PubMed ID: 3921568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the in vitro fibrinolytic activities of low and high molecular weight single-chain urokinase-type plasminogen activator.
    de Munk GA; Groeneveld E; Rijken DC
    Thromb Haemost; 1993 Sep; 70(3):481-5. PubMed ID: 8259553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The plasminogen content of commercial preparations and of normal donor plasma in relation to the plasmin content of the 1st international plasmin reference preparation.
    Wolf P
    Thromb Haemost; 1979 Aug; 42(2):582-95. PubMed ID: 159512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of plasminogen activators and plasminogen with heparin: effect of ionic strength.
    Rijken DC; de Munk GA; Jie AF
    Thromb Haemost; 1993 Nov; 70(5):867-72. PubMed ID: 8128448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight into the profibrinolytic activity of dermatan sulfate: effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators.
    Castañon MM; Gamba C; Kordich LC
    Thromb Res; 2007; 120(5):745-52. PubMed ID: 17270255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New thrombolytic agents].
    Nguyen G; Samama M
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrin-specific thrombolytic agents.
    Collen D
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The susceptibility of plasma to activation of fibrinolysis.
    Stief TW
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):123-5. PubMed ID: 8457639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein.
    Binnema DJ; Dooijewaard G; Turion PN
    Thromb Haemost; 1991 Feb; 65(2):144-8. PubMed ID: 1905069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actin stimulates plasmin generation by tissue and urokinase-type plasminogen activators.
    Lind SE; Smith CJ
    Arch Biochem Biophys; 1993 Nov; 307(1):138-45. PubMed ID: 8239651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.